Revolution Medicines, Inc.

NASDAQ:RVMD

Biotechnology

Healthcare
$159.82 +2.28%

+$3.60 today

Market cap
$34.57B
Beta
1.41
P/E (TTM)
-23.3
EPS (TTM)
-$6.92
52W Low $34.00High $166.50

Volume 2.34M

Average 3.10M

RVMD Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Revolution Medicines, Inc.NASDAQ: RVMD

Short-term Debt · Q2 FY2026 · quarter ended Jun 2026

Short-term debt remains negative

Q2 FY2026 short-term debt was $0, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How RVMD compares with its peers on the latest reported figures

  • RVMD's Jun 2026 short-term debt of $0 is the 5th highest of the 11 companies compared; the peer median is $0.
  • Short-term debt amounts to 0.0% of total assets for RVMD, versus a peer median of 0.0%.
RVMD Competitors Peer median
Short-term Debt for RVMD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VSTMVerastem, Inc.Mar 2026$5.8M +188.3%+24.8%2.5%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$3.79M ——2.9%
TNGXTango Therapeutics, Inc.Sep 2026$3.06M ——0.3%
IDYAIDEAYA Biosciences, Inc.Mar 2026$350K ——0.0%
RVMDRevolution Medicines, Inc.Jun 2026$0 ——0.0%
ERASErasca, Inc.Sep 2026$0 -100.0%—0.0%
RLAYRelay Therapeutics, Inc.Jun 2026$0 ——0.0%
ELVNEnliven Therapeutics, Inc.Sep 2026$0 ——0.0%
NRIXNurix Therapeutics, Inc.Aug 2026$0 ——0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$0 —+7.8%0.0%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding RVMD) $0+44.2%+16.3%0.0%

Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents108.5M161.41M696.15M543.06M383.75M
Short-term Investments468.56M483.53M1.16B1.75B1.64B
Net Receivables5.93M4.67M1.25M00
Inventory00000
Other Current Assets010.57M25.07M38.33M49.36M
Total Current Assets589.77M660.19M1.88B2.33B2.08B
Property, Plant & Equipment (Net)71.24M73.74M100.01M141.82M165.28M
Goodwill14.61M14.61M14.61M14.61M14.61M
Intangible Assets59.88M58.81M57.74M56.67M55.8M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.5M4.59M10.06M17.57M43.79M
Total Non-current Assets148.22M151.75M182.42M230.67M279.47M
Total Assets737.99M811.93M2.06B2.56B2.35B
Account Payables14.06M21.31M61.79M54.43M64.62M
Short-term Debt00000
Tax Payables00000
Deferred Revenue12.36M4.46M000
Other Current Liabilities10.16M13.79M27.51M31.36M66.05M
Total Current Liabilities60.35M61.98M143.85M163.91M290.42M
Long-term Debt0000142.23M
Deferred Tax Liabilities7.44M7.03M3.12M2.35M2.35M
Deferred Revenue (Non-current)6.57M0000
Other Non-current Liabilities634K301K7.97M3.86M288.2M
Total Non-current Liabilities75.07M64.76M91.66M129.18M432.79M
Total Liabilities135.42M126.74M235.51M293.1M723.21M
Common Stock8K9K16K18K19K
Retained Earnings(452.64M)(701.34M)(1.14B)(1.74B)(2.87B)
Accumulated OCI(376K)(1.78M)544K1.32M3.24M
Other Stockholders Equity00000
Minority Interest00000
Total Equity602.57M685.19M1.83B2.27B1.63B
Total Debt66.63M64.21M87.94M135.84M158.7M
Net Debt(41.86M)(97.21M)(608.2M)(407.22M)(225.04M)

Revolution Medicines, Inc.

NASDAQ:RVMD

Intrinsic Alpha fair value

Locked

Current Price

$159.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.